Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
59 hedge funds and large institutions have $97.9M invested in Adverum Biotechnologies in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 8 closing their positions.
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
4% more funds holding
Funds holding: 57 → 59 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.07% less ownership
Funds ownership: 6.53% → 6.46% (-0.07%)
6% less capital invested
Capital invested by funds: $104M → $97.9M (-$6.45M)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$4.82M |
| 2 |
Citigroup
New York
|
+$856K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$426K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$228K |
| 5 |
Renaissance Technologies
New York
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$2.23M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.92M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.48M |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
-$578K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$509K |
ADVM Hedge Fund Activity: Q3 2023 in Review
59 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2023, worth a combined $97.9M — down 6.2% from $104M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ADVM positions and 8 closed out — a net gain of 2 holders — while 15 added to existing stakes and 20 trimmed.
The largest buyer was VR Adviser, adding an estimated $4.82M. The largest seller was BML Capital Management, cutting an estimated $2.23M.
- 59 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2023, up from 57 in Q2 2023.
- Funds reported $97.9M of Adverum Biotechnologies stock for Q3 2023, down 6.2% quarter-over-quarter.
- 10 funds opened new Adverum Biotechnologies positions in Q3 2023 and 8 closed out, a net change of +2 holders.
- The largest Adverum Biotechnologies buyer in Q3 2023 was VR Adviser, an estimated $4.82M added.
- The largest Adverum Biotechnologies seller in Q3 2023 was BML Capital Management, an estimated $2.23M sold.
Based on aggregated 13F filings for Q3 2023.